![BofA: Lamborghini in Volkswagen portfolio worth billions, up to EUR 40 per share](https://i-invdn-com.investing.com/news/LYNXMPEB3S07F_S.jpg)
Please try another search
For the fiscal year ended 31 March 2014, Arvind Remedies Ltd revenues increased 36% to RS9.63B. Net income increased 35% to RS584.9M. Revenues reflect Domestic segment increase of 38% to RS10.1B. Net income was partially offset by Interest Expenses increase of 29% to RS798.8M (expense), R & D Expenses increase from RS1.4M to RS102.6M (expense). Dividend per share decreased from RS1.00 to RS0.80.
Period Ending: | Jun 30, 2013 | Mar 31, 2013 | Dec 31, 2012 | Sep 30, 2012 |
---|---|---|---|---|
Total Revenue | 1838.4 | 2162.79 | 1802.3 | 1698.79 |
Gross Profit | 479.41 | 587.01 | 415.01 | 379.18 |
Operating Income | 367.47 | 413.08 | 318.99 | 289.99 |
Net Income | 165.3 | 151.82 | 122.06 | 69.67 |
Period Ending: | Jun 30, 2013 | Mar 31, 2013 | Dec 31, 2012 | Sep 30, 2012 |
---|---|---|---|---|
Total Assets | 8665.84 | 7318.02 | ||
Total Liabilities | 6683.47 | 5646.36 | ||
Total Equity | 1982.38 | 1671.66 |
Period Ending: | Jun 30, 2013 | Mar 31, 2013 | Dec 31, 2012 | Sep 30, 2012 |
---|---|---|---|---|
Period Length: | 0 Months | 0 Months | 0 Months | 0 Months |
Cash From Operating Activities | ||||
Cash From Investing Activities | ||||
Cash From Financing Activities | ||||
Net Change in Cash |
Unlock access to over 1000 metrics with InvestingPro
View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review